Strategic leadership New CEO appointment signals potential strategic shift and upcoming Phase IIb trial for EXN407, presenting a window for partnerships or advisory engagements and early access discussions with decision-makers.

Clinical momentum Lead candidate EXN407 shows positive Phase Ib/IIa signals for diabetic retinopathy and diabetic macular edema, indicating opportunities to engage ophthalmology clinics, payers, and contract research organizations for trial expansion and potential companion diagnostics.

Partnership history Past Janssen collaboration and eye-drop focus highlight a track record with big pharma; leverage this to rekindle partnerships or licensing discussions around platform technology, non-invasive therapeutics, and regional manufacturing.

Financial profile StartupFunding modest with recent rounds and zero revenue; target opportunities include strategic investments, co-development deals, and milestone-driven collaborations with risk-sharing structures aligned to Phase IIb timelines.

Market readiness Non-invasive, topical approach for retinal vascular diseases aligns with high-need areas like diabetic retinopathy and macular edema; pursue opportunities with ophthalmology networks, specialty pharmacies, and payer-proof value demonstrations to accelerate adoption.